Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01702805
Other study ID # NICHD-NRN-0050
Secondary ID U01HL112776U01HL
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date December 2012
Est. completion date August 2025

Study information

Verified date March 2024
Source NICHD Neonatal Research Network
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the TOP trial is to determine whether higher hemoglobin thresholds for transfusing ELBW infants resulting in higher hemoglobin levels lead to improvement in the primary outcome of survival and rates of neurodevelopmental impairment (NDI) at 22-26 months of age, using standardized assessments by Bayley.


Description:

Long-term outcomes of extremely low birth weight (ELBW) preterm infants, those weighing less than or equal to 1000 g at birth, are poor and pose a major health care burden. Virtually all of these infants are transfused, but at inconsistent hemoglobin (Hgb) thresholds. The investigators propose in TOP to randomize infants less than or equal to 1000 g BW and gestational age at least 22 weeks but less than 29 weeks to receive red blood cell (RBC) transfusions according to one of two strategies of Hgb thresholds, either a high Hgb (liberal transfusion) or a low Hgb (restrictive transfusion) algorithm. It is currently unknown which transfusion strategy is superior. TOP is powered to demonstrate which strategy reduces the primary outcome of death or neurodisability in survivors at 22-26 months. A secondary study entitled "Effect of Blood Transfusion Practices on Cerebral and Somatic Oximetry", also known as the NIRS study, will determine differences in cerebral oxygenation and fractional tissue oxygen extraction with NIRS between high and low hemoglobin threshold groups during red blood cell transfusions. The investigators also propose to determine whether abnormal cerebral NIRS measures are a better predictor of NDI than hemoglobin alone and whether abnormal mesenteric NIRS measures are associated with the development of NEC within the 48 hours following a transfusion. A secondary study entitled "Economic Evaluation Ancillary to the Transfusion of Prematures Randomized Controlled Trial" will determine whether higher transfusion threshold will result in lower total costs to society over the first 22 to 26 corrected months of life and estimate the incremental cost-effectiveness ratio for survival without neurodevelopmental impairment, from the perspective of society, the third-party payer, and the family. Extended follow-up: Subjects will be seen for a follow-up visit at 5-6 years corrected age to assess neurological and functional outcomes at early school age based on neonatal transfusion threshold.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1824
Est. completion date August 2025
Est. primary completion date January 2020
Accepts healthy volunteers No
Gender All
Age group N/A to 48 Hours
Eligibility Inclusion Criteria: - Birth weight less than or equal to 1000 grams. - Gestational age at least 22 weeks but less than 29 weeks - Admitted to the NICU within 48 hours of life Exclusion Criteria: - Considered nonviable by the attending neonatologist - Cyanotic congenital heart disease - Parents opposed to the transfusion of blood - Parents with hemoglobinopathy or congenital anemia - In-utero fetal transfusion - Twin-to-twin transfusion syndrome - Isoimmune hemolytic disease - Lack of parental consent - Severe acute hemorrhage, acute shock, sepsis with coagulopathy, or need for perioperative transfusion. - Prior blood transfusion on clinical grounds beyond the first 6 hours of life - Infant has received erythropoietin prior to randomization, or is intended to receive erythropoietin through the neonatal course - Congenital condition, other than premature birth, that adversely affects life expectancy or neurodevelopment. - High probability that the family is socially disorganized to the point of being unable to attend follow-up at 22-26 months.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Liberal Cell Transfusion

Restricted red cell transfusion


Locations

Country Name City State
United States University of New Mexico Albuquerque New Mexico
United States Emory University Atlanta Georgia
United States University of Alabama at Birmingham Birmingham Alabama
United States Cincinnati Children's Medical Center Cincinnati Ohio
United States Case Western Reserve University, Rainbow Babies and Children's Hospital Cleveland Ohio
United States Research Institute at Nationwide Children's Hospital Columbus Ohio
United States University of Texas Southwestern Medical Center at Dallas Dallas Texas
United States Wayne State University Detroit Michigan
United States Duke University Durham North Carolina
United States RTI International Durham North Carolina
United States University of Texas Health Science Center at Houston Houston Texas
United States Indiana University Indianapolis Indiana
United States University of Iowa Iowa City Iowa
United States Children's Mercy Hospital Kansas City Missouri
United States University of California - Los Angeles Los Angeles California
United States Stanford University Palo Alto California
United States Univeristy of Pennsylvania Philadelphia Pennsylvania
United States Brown University, Women & Infants Hospital of Rhode Island Providence Rhode Island
United States University of Rochester Rochester New York
United States University of Utah Salt Lake City Utah

Sponsors (3)

Lead Sponsor Collaborator
NICHD Neonatal Research Network Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Death or Neurodevelopmental Impairment A composite outcome that measures the occurrence of death or neurodevelomental impairment between birth and 22-26 months corrected age. Birth to 22-26 months corrected age
Primary Death This is measured as Yes if an infant died between birth and 22-26 months corrected age; Otherwise, No. Birth to 22-26 months corrected age
Primary Neurodevelopmental Impairment This is measured as Yes if any hearing impairment or visual impairment is noted, if severe or moderate cerebral palsy is noted, or if the cognitive score of the Bayley III score is more than 1 standard deviation below the average; Otherwise, No. at 22-26 months corrected age
Primary Cognitive Delay This is measured as Yes if the Bayley Scale of Infant and Toddler Development (BSID)-III cognitive score is more than 1 standard deviation below the average; Otherwise, No. at 22-26 months corrected age
Primary Moderate or Severe Cerebral Palsy This is measured as Yes if the Gross Motor Function Classification System (GMFCS) score is level II or higher; Otherwise, No. Higher values of the GMFCS are worse than lower values; a level of "I" denotes mild cerebral palsy (CP); level "II" or "III" moderate CP; level "IV" or "V" severe CP. at 22-26 months corrected age
Primary Severe Vision Impairment This is measured as Yes if the corrected visual acuity in the better eye of less than 20/200; Otherwise, No. at 22-26 months corrected age
Primary Severe Hearing Impairment This is measured as Yes if bilateral hearing loss occurred for which hearing aids or cochlear implants were warranted; Otherwise, No. at 22-26 months corrected age
Secondary Survival to Discharge Without Severe Complications This is measured as Yes if survived to discharge without severe morbidity, defined as bronchopulmonary dysplasia, retinopathy of prematurity (stage 3 or higher or requiring treatment), or serious brain abnormality; Otherwise, No. Birth to initial hospital discharge or to death if it occurs earlier (a median of 97 days)
Secondary Bronchopulmonary Dysplasia, Diagnosed on the Basis of the Need for Supplemental Oxygen After a Standardized Oxygen Reduction Test at 36 Weeks of Postmenstrual Age This is measured as Yes if experienced bronchopulmonary dysplasia, diagnosed on the basis of the need for supplemental oxygen after a standardized oxygen reduction test at 36 weeks of postmenstrual age; Otherwise, No. at 36 weeks postmenstrual age
Secondary Retinopathy of Prematurity Stage >=3 or Treatment for That Condition Received This is measured as Yes if experienced Retinopathy of Prematurity (ROP) Stage >=3 or received treatment for that condition; Otherwise, No. Higher stages of ROP indicate a worse outcome; the stages range from 1 for "mild" disease, to 5 for "severe" disease. Birth to initial hospital discharge or to death if it occurs earlier (a median of 97 days)
Secondary Grade 3 or 4 Intraventricular Hemorrhage, Cystic Periventricular Leukomalacia, or Ventriculomegaly Diagnosed on Ultrasonographic Examination This is measured as Yes if experienced Grade 3 or 4 intraventricularhemorrhage, cystic periventricular leukomalacia, or ventriculomegaly diagnosed on ultrasonographic examination; Otherwise, No. Birth to initial hospital discharge or to death if it occurs earlier (a median of 97 days)
Secondary Necrotizing Enterocolitis, Bell's Stage >=2 This is measured as Yes if experienced necrotizing enterocolitis (NEC), Bell's stage >=2; Otherwise, No. Higher scores of Bell's staging criteria denote a worse outcome, where "1" denotes suspect, "2" definite and "3" advanced NEC. Birth to initial hospital discharge or to death if it occurs earlier (a median of 97 days)
Secondary Number of Transfusions Per Infant This is measured as the number of protocol compliant transfusions, clinically justified non-protocol transfusions and unjustified non-protocol transfusions (violations) Birth, up to the earliest of: death, hospital discharge, or 36 weeks postmenstrual age (PMA)
Secondary Weight-for-age: Z-score This is measured as the weight-for-age Z-score at 36 weeks postmenstrual age or at initial hospital discharge, whichever occurs first. The Z-score is determined using Olsen percentile curves, and is derived from a normal distribution, where 0 designates average weight-for-age, and negative scores denote less than average weight-for-age. at 36 weeks postmenstrual age or initial hospital discharge, whichever occurs first
Secondary Length-for-age: Z-score This is measured as the length-for-age Z-score at 36 weeks postmenstrual age or at initial hospital discharge, whichever occurs first. The Z-score is determined using Olsen percentile curves, and is derived from a normal distribution, where 0 designates average length-for-age, and negative scores denote less than average length-for-age. at 36 weeks postmenstrual age or initial hospital discharge, whichever occurs first
Secondary Head Circumference-for-age: Z-score This is measured as the head circumference-for-age Z-score at 36 weeks postmenstrual age or at initial hospital discharge, whichever occurs first. The Z-score is determined using Olsen percentile curves, and is derived from a normal distribution, where 0 designates average head circumference-for-age, and negative scores denote less than average head circumference-for-age. at 36 weeks postmenstrual age or initial hospital discharge, whichever occurs first
Secondary Postmenstrual Age at Final Trachael Extubation This is measured as the average postmenstrual age (in weeks) at final tracheal extubation in infants who were intubated. at final trachael extubation, assessed from birth up to the earliest of: death, hospital discharge, or 36 weeks postmenstrual age
Secondary Postmenstrual Age at Final Caffeine Dose in Infants Who Received Caffeine Treatment This is measured as the average postmenstrual age (in weeks) at final caffeine dose in infants who received caffeine treatment. at final caffeine dose, assessed from birth up to the earliest of: death, hospital discharge, or 36 weeks postmenstrual age
Secondary Length of Stay This is measured as the length of stay (in days) up to initial hospital discharge or death, whichever occurred first. at initial hospital discharge or at death if it occurs earlier (a median of 97 days)
Secondary Time to Full Enteral Feeding This is measured as the amount of days it took for full enteral feeding to occur. at first full enteral feeding, assessed from birth up to initial hospital discharge or to death if it occurs earlier (a median of 97 days)
Secondary Severe Cerebral Palsy This is measured as Yes if Gross Motor Function Classification System (GMFCS) is levels IV or V; Otherwise, No. Higher values of the GMFCS are worse than lower values; a level of "I" denotes mild cerebral palsy (CP); level "II" or "III" moderate CP; level "IV" or "V" severe CP. at 22-26 months corrected age
Secondary Hydrocephalus Shunt This is measured as Yes if experienced Hydrocephalus shunt by follow-up; Otherwise, No. Initial hospital discharge to 22-26 months corrected age
Secondary Microcephaly This is measured as a head circumference-for-age Z-score of less than -2; Otherwise, No. The Z-score is determined using WHO percentile curves, and is derived from a normal distribution, where 0 designates average head circumference-for-age, and negative scores denote less than average head circumference-for-age. at 22-26 months corrected age
Secondary Seizure Disorder This is measured as Yes if experienced one or more seizures since discharge or of regular use of anticonvulsants or seizure medications; Otherwise, No. Initial hospital discharge to 22-26 months corrected age
Secondary Respiratory Disease Necessitating Readmission Before Follow-up This is measured as Yes if obtained Respiratory disease necessitating readmission before follow-up; Otherwise, No. Initial hospital discharge to 22-26 months corrected age
Secondary Composite Language Score Less Than 85 This is measured as Yes if scored less than 85 on the Bayley Scale of Infant and Toddler Development (BSID)-III composite language score; Otherwise, No. Higher scores indicate better performance. Composite BSID-III scores of less than 85 are less than 1 standard deviation below the mean of 100. at 22-26 months corrected age
Secondary Composite Motor Score Less Than 85 This is measured as Yes if scored less than 85 on the Bayley Scale of Infant and Toddler Development (BSID)-III composite motor score; Otherwise, No. Higher scores indicate better performance. Composite BSID-III scores of less than 85 are less than 1 standard deviation below the mean of 100. at 22-26 months corrected age
Secondary Composite Cognitive Score Less Than 70 This is measured as Yes if scored less than 85 on the Bayley Scale of Infant and Toddler Development (BSID)-III composite cognitive score; Otherwise, No. Higher scores indicate better performance. Composite BSID-III scores of less than 70 are less than 2 standard deviations below the mean of 100. at 22-26 months corrected age
Secondary Composite Language Score Less Than 70 This is measured as Yes if scored less than 85 on the Bayley Scale of Infant and Toddler Development (BSID)-III composite language score; Otherwise, No. Higher scores indicate better performance. Composite BSID-III scores of less than 70 are less than 2 standard deviations below the mean of 100. at 22-26 months corrected age
Secondary Composite Motor Score Less Than 70 This is measured as Yes if scored less than 85 on the Bayley Scale of Infant and Toddler Development (BSID)-III composite motor score; Otherwise, No. Higher scores indicate better performance. Composite BSID-III scores of less than 70 are less than 2 standard deviations below the mean of 100. at 22-26 months corrected age
See also
  Status Clinical Trial Phase
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03341338 - Genes-in-Action - Hepcidin Regulation of Iron Supplementation
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT02912494 - A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT03822884 - Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers Phase 1
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT02912533 - A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02603250 - Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda N/A
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Completed NCT02310113 - Transfusion and Skeletal Muscle Tissue Oxygenation N/A
Withdrawn NCT01934842 - A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Completed NCT01432717 - Study of ACE-536 in Healthy Postmenopausal Women Phase 1
Completed NCT01458028 - Age and Gender Effects on the Pharmacokinetics of BAY85-3934 Phase 1